NovaBridge Biosciences

NovaBridge Biosciences announced it will hold its Annual General Meeting (AGM) on September 8, 2026, at its Shanghai office. Shareholders of record as of July 27, 2026, are eligible to vote. A key resolution to be submitted for shareholder approval is the removal of Ms. Xin Liu from her position as a director, which the Board recommends voting "FOR" to enhance corporate governance and operational efficiency. The company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025, is also available.

NovaBridge Biosciences' Board of Directors adopted the 2026 Omnibus Share Incentive Plan on July 13, 2026. This plan authorizes the issuance of up to 11,960,000 Shares, equivalent to 5,200,000 American Depositary Shares, plus additional shares from predecessor plans. The plan also includes an annual increase provision of up to 3% of outstanding shares from 2027 to 2036, and is designed to attract, retain, and motivate key personnel through various equity and cash-based awards.

NovaBridge Biosciences announced a change in its independent registered public accounting firm. On June 16, 2026, the Audit Committee dismissed PricewaterhouseCoopers LLP (PwC) and immediately appointed Deloitte Touche Tohmatsu Certified Public Accountants LLP (Deloitte) for the fiscal year ending December 31, 2026. The company stated there were no disagreements with PwC on accounting or auditing matters, other than previously reported material weaknesses related to ineffective information technology general controls (ITGCs).

NovaBridge Biosciences announced that the FDA has granted Fast Track Designation to givastomig for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas. This designation aims to accelerate the development and review of therapies for serious conditions with unmet medical needs. The company expects to begin a registrational Phase 3 trial as early as Q4 2026 and present detailed Phase 1b data in H2 2026.

NovaBridge Biosciences announced that its senior management team will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The participation will include a company presentation at 3:10 PM ET and one-on-one investor meetings, with a webcast accessible for 90 days. The company also highlighted its pipeline, including givastomig, which is in a global randomized Phase 2 study, and VIS-101, which completed a Phase 2a study and is set to begin a Phase 2b study in H2 2026.